311 related articles for article (PubMed ID: 30396776)
1. Pathological roles of the homeostatic chemokine CXCL12.
Janssens R; Struyf S; Proost P
Cytokine Growth Factor Rev; 2018 Dec; 44():51-68. PubMed ID: 30396776
[TBL] [Abstract][Full Text] [Related]
2. The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.
García-Cuesta EM; Santiago CA; Vallejo-Díaz J; Juarranz Y; Rodríguez-Frade JM; Mellado M
Front Endocrinol (Lausanne); 2019; 10():585. PubMed ID: 31507535
[TBL] [Abstract][Full Text] [Related]
3. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
4. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.
Janssens R; Mortier A; Boff D; Ruytinx P; Gouwy M; Vantilt B; Larsen O; Daugvilaite V; Rosenkilde MM; Parmentier M; Noppen S; Liekens S; Van Damme J; Struyf S; Teixeira MM; Amaral FA; Proost P
Biochem Pharmacol; 2017 May; 132():92-101. PubMed ID: 28322746
[TBL] [Abstract][Full Text] [Related]
5. The unique structural and functional features of CXCL12.
Janssens R; Struyf S; Proost P
Cell Mol Immunol; 2018 Apr; 15(4):299-311. PubMed ID: 29082918
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
[TBL] [Abstract][Full Text] [Related]
7. Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.
Murphy PM; Heusinkveld L
Cytokine; 2018 Sep; 109():2-10. PubMed ID: 29398278
[TBL] [Abstract][Full Text] [Related]
8. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.
Gao X; Abdelkarim H; Albee LJ; Volkman BF; Gaponenko V; Majetschak M
PLoS One; 2018; 13(9):e0204041. PubMed ID: 30248140
[TBL] [Abstract][Full Text] [Related]
9. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
10. Atypical Chemokine Receptor 3 "Senses" CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT; Chen Q; Tesmer JJG; Handel TM
Mol Pharmacol; 2023 Oct; 104(4):174-186. PubMed ID: 37474305
[TBL] [Abstract][Full Text] [Related]
11. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.
Tu CC; Arnolds KL; O'Connor CM; Spencer JV
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840
[TBL] [Abstract][Full Text] [Related]
12. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma.
Rusetska N; Kowalski K; Zalewski K; Zięba S; Bidziński M; Goryca K; Kotowicz B; Fuksiewicz M; Kopczynski J; Bakuła-Zalewska E; Kowalik A; Kowalewska M
J Clin Pathol; 2022 May; 75(5):324-332. PubMed ID: 33692092
[TBL] [Abstract][Full Text] [Related]
13. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
14. The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.
Smit MJ; Schlecht-Louf G; Neves M; van den Bor J; Penela P; Siderius M; Bachelerie F; Mayor F
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():541-563. PubMed ID: 32956018
[TBL] [Abstract][Full Text] [Related]
15. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.
Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF
J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219
[TBL] [Abstract][Full Text] [Related]
16. Roles of chemokine CXCL12 and its receptors in ischemic stroke.
Wang Y; Huang J; Li Y; Yang GY
Curr Drug Targets; 2012 Feb; 13(2):166-72. PubMed ID: 22204316
[TBL] [Abstract][Full Text] [Related]
17. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S; Gouwy M; Proost P
Cell Mol Immunol; 2023 Mar; 20(3):217-251. PubMed ID: 36725964
[TBL] [Abstract][Full Text] [Related]
18. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
19. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.
Hanes MS; Salanga CL; Chowdry AB; Comerford I; McColl SR; Kufareva I; Handel TM
J Biol Chem; 2015 Sep; 290(37):22385-97. PubMed ID: 26216880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
